- Home
- BDC vs PTGX Comparison
BDC vs PTGX Comparison
Compare BDC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDC | PTGX |
|---|---|---|
| Founded | 1902 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.4B |
| IPO Year | 1993 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BDC | PTGX |
|---|---|---|
| Price | $121.92 | $89.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $136.67 | $86.44 |
| AVG Volume (30 Days) | 241.4K | ★ 898.7K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | ★ 30.90 | N/A |
| EPS | ★ 5.62 | 0.72 |
| Revenue | ★ $2,661,116,000.00 | $209,217,000.00 |
| Revenue This Year | $10.48 | N/A |
| Revenue Next Year | $5.11 | $296.47 |
| P/E Ratio | ★ $21.70 | $124.48 |
| Revenue Growth | ★ 13.42 | N/A |
| 52 Week Low | $83.18 | $33.70 |
| 52 Week High | $133.77 | $93.25 |
Technical Indicators
Market Signals| Indicator | BDC | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 64.93 | 64.67 |
| Support Level | $110.78 | $83.52 |
| Resistance Level | $114.98 | $90.85 |
| Average True Range (ATR) | 3.26 | 2.63 |
| MACD | 1.38 | -0.33 |
| Stochastic Oscillator | 97.56 | 83.62 |
Price Performance
Historical ComparisonAbout BDC Belden Inc
Belden designs, manufactures, and markets advanced networking, connectivity, and cable solutions for industrial automation, smart buildings, and broadcast markets. Their portfolio includes cables, connectors, and networking equipment, enabling secure, reliable data transmission for applications in data centers, healthcare, education, hospitality, and more.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.